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Few studies have examined whether the Xpert MTB/RIF test 
improves time to treatment initiation for persons with multi-
drug-resistant tuberculosis (MDR TB). We determined the 
impact of this test in Latvia, where it was introduced in 2010. 
After descriptive analyses of pulmonary MDR TB patients in 
Latvia during 2009–2012, time to treatment initiation was cal-
culated, and univariate and multivariable accelerated failure 
time models were constructed. Univariate results showed 
strong evidence of an association between having rifampin-
resistant TB detected by Xpert MTB/RIF and reduced time 
to treatment initiation versus the test not being used. A mul-
tivariable model stratifying by previous TB showed similar 
results. Our finding that in Latvia, time to treatment initiation 
was decreased for MDR TB cases that were rifampin-resis-
tant TB by XpertMTB/RIF has implications for the use of this 
test in other settings with a high burden of MDR TB in which 
rifampin resistance is highly predictive of MDR TB.
Timely diagnosis and treatment of multidrug-resistant tuberculosis (MDR TB), of which there were an es-
timated 480,000 cases in 2014, have been identified as a 
critical challenge for TB control (1,2). In 2010, the World 
Health Organization endorsed the Xpert MTB/RIF (Myco-
bacterium tuberculosis/rifampin test, hereafter referred to 
as Xpert; Cepheid, Sunnyvale, CA, USA) as a rapid test 
for the diagnosis of TB, including rifampin-resistant cases, 
citing a strong recommendation in their 2013 policy update 
for its use “as an initial diagnostic test in individuals sus-
pected of having MDR TB or HIV-associated TB” (3,4).
Implications of the implementation of Xpert for a 
country are closely linked to where in the clinical path-
way it is placed and how clinicians view the technology. 
Although many studies (and reviews) have assessed sen-
sitivity, specificity, and predictive values of Xpert (5), few 
studies have examined the impact of this technology on 
the rapidity with which appropriate treatment is given to 
TB patients (6–11). Even fewer studies have assessed the 
effects of Xpert on time to MDR TB treatment initiation 
for MDR TB patients. In South Africa, a reduction in time 
from first diagnostic sputum collection to treatment com-
mencement from 43 days to 17 days was found when an 
algorithm based on Xpert was compared with an algorithm 
based on the line probe assay (LPA) (12).
Despite successes in TB and MDR TB control in re-
cent years, Latvia is classified as having a high burden of 
MDR TB; in 2014, 8.2% of new TB cases and 30% of re-
treatment TB cases were estimated to be MDR (2,13). Ab-
solute case numbers (48 new and 37 re-treatment in 2014) 
are relatively low, which is a reflection of TB incidence and 
population size (13). A total of 99% of new cases and 86% 
of re-treatment cases were reported by the World Health 
Organization to have been tested phenotypically or geno-
typically for rifampin-resistant or MDR TB in 2014; the 
86% reflects clinical use of prior drug-susceptibility results 
for re-treatment cases. All MDR TB cases were tested for 
resistance to second-line drugs in 2013 (14). Access to 
MDR TB treatment is universal in Latvia. Most MDR TB 
patients are hospitalized, at least for the initial treatment 
period, in Riga, the capital of Latvia.
Latvia has 2 Xpert systems, both in Riga, where Xpert 
has been used since 2010. Xpert was initially targeted to-
ward groups at high risk for MDR TB (e.g., contacts of 
persons with MDR TB). Since 2012, wider use of Xpert 
was promoted (e.g., for re-treatment cases). Two diagnos-
tic pathways for MDR TB patients were used (Figure 1). 
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Decreased Time to Treatment Initiation for MDR TB
When Xpert was available, its results determined whether 
a patient was initially given treatment for MDR TB. In the 
absence of Xpert, patients were initially given first-line 
drugs. In Latvia, rifampin resistance is a good predictor of 
MDR TB (15). The positive predictive value (PPV) of ri-
fampin resistance for MDR is partly determined by MDR 
TB prevalence (at an MDR TB prevalence >14.2% for 
new TB cases and >20% for re-treatment cases, the PPV 
is 90%) (16).
We used surveillance data to examine the relationship 
between use of Xpert and time to treatment initiation for 
MDR TB patients in Latvia. We aimed to provide useful 
data for clinicians and policy makers evaluating implemen-
tation of Xpert in settings with a high burden of MDR TB in 
which rifampin resistance is a good indicator of MDR TB.
Methods
The treatment cohorts for MDR TB patients in Latvia dur-
ing 2009–2012, excluding cases in prisoners, were ob-
tained from the national MDR TB surveillance system, 
together with their demographic and clinical data (supple-
mented from paper records where necessary). Persons with 
only extrapulmonary MDR TB were excluded, which is 
consistent with primary use of Xpert. Ethical approval for 
the study was provided by the ethics committee of Riga 
Stradins University. Informed consent was not required be-
cause this study used an anonymous surveillance dataset.
Age was grouped into 20-year categories (<20, 20–39, 
40–59, and >60 years); nationality as Latvian or other; 
residency region in Latvia as Riga or elsewhere (consis-
tent with diagnostic methods available in Riga); and social 
risk factors (history of imprisonment, history of or current 
drug abuse, current homelessness, current dependence on 
alcohol) into a single dichotomous variable of >1 risks 
versus none or unknown. Site of disease was classified as 
pulmonary or pulmonary and extrapulmonary and HIV sta-
tus as positive, negative, or unknown. Use of Xpert was 
categorized as not conducted versus conducted for descrip-
tive analysis; the conducted category was subdivided into 
conducted and rifampin-resistant TB and conducted and 
negative result for rifampin-resistant TB. History of TB 
and sex were treated as binary variables. Reporting date 
was grouped into year of reporting.
Time between date patient samples were obtained 
and date of MDR TB treatment initiation (start of MDR 
TB treatment was defined as start of use of second-line 
drugs) was calculated and used as the scale (time since en-
try) for regression analysis. Persons for whom either date 
was missing were excluded. When persons started MDR 
TB treatment on the day that their samples were obtained, 
time to treatment initiation was set to 0.25 days for regres-
sion analysis.
Demographic and clinical characteristics of patients 
were described, and time-to-event (MDR TB treatment 
initiation) data plotted, including using Kaplan-Meier plots 
to examine the proportion of persons who had completed 
treatment at given time points. Before regression model-
ing, we created a conceptual framework of the relationship 
between main exposure (Xpert use) and outcome (time to 
initiation of MDR TB treatment) (Figure 2) and used this 
framework to identify a priori and potential confounders, as 
well as effect modifiers (17).
We initially assessed use of linear regression to mea-
sure the effect of Xpert use on time to treatment initia-
tion. However, the highly skewed distribution of time to 
treatment initiation (even after log or reciprocal transfor-
mation) showed that this technique was not appropriate. 
Accelerated failure time (AFT) models were chosen as 
an alternative technique. These models assume that the 
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Figure 1. Diagnostic pathways for patients with multidrug-resistant 
tuberculosis, Latvia, 2012. A) With use of Xpert MTB/RIF; B) 
without use of Xpert MTB/RIF. A line probe assay was used if 
Xpert and DST showed discordant results. MTB, Mycobacterium 
tuberculosis; RIF, rifampin; TB, tuberculosis; DST, drug sensitivity 
testing; Xpert, Xpert MTB/RIF.
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fraction of persons surviving (i.e., not receiving appropri-
ate treatment) in 1 group at any given time point is propor-
tional to the equivalent fraction of the other group.
We tested this assumption by using quantile–quantile 
plots, which plot quantiles of survival distribution for the 
exposed group against those for the unexposed group. AFT 
models are considered appropriate if these plots approxi-
mate a straight line. We then used a univariate model to 
calculate the time ratio, 95% CI, and p value for the asso-
ciation between Xpert use and time to MDR TB treatment 
initiation. The time ratio represents the relative time to 
MDR TB treatment initiation between groups (i.e., a ratio 
of 0.9 indicates that persons in the exposed [tested] group 
are 10% more likely to have initiated treatment than those 
in the unexposed [not tested] group). In a scenario in which 
everyone initiates treatment, a ratio of 0.9 indicates a 10% 
reduction in time to initiation among exposed persons. An 
exponential distribution of survival times was assumed; a 
Weibull distribution was also investigated in preliminary 
analyses, but was found to fit the data poorly.
Exposures classified as a priori confounders (sex, age, 
previous TB) and potential confounders associated with 
outcome and Xpert use, but not on the causal pathway be-
tween these 2 factors, were included in the initial multi-
variable model. We used a backward deletion strategy in 
which potential confounders were individually removed 
and the full (all potential confounders present) and reduced 
(1 potential confounder removed) models were compared 
by using square roots of estimated mean squared errors 
(18,19). Thus, a final model was derived while simultane-
ously enabling assessment of confounding, multicollinear-
ity and maintenance of a priori confounders.
Likelihood ratio tests were conducted to test for linear-
ity (age, year) and effect modification. Region and previous 
TB were pre-identified as potential effect modifiers. Year 
of reporting was excluded from initial modeling so that 
data for 2009 could be used, but was planned to be includ-
ed as a confounder during sensitivity analysis. Analysis 
was conducted by using Stata 13 (StataCorp LP, College 
Station, TX, USA) and Excel (Microsoft, Redmond, WA, 
USA) software.
Results
Of 398 persons in treatment cohorts in Latvia during 2009–
2012, five persons were excluded because of missing dates 
and 6 more were excluded because they had only extrapul-
monary disease. This exclusion resulted in 387 pulmonary 
TB patients, of whom 262 did not have Xpert testing (100% 
for 2009, 84% for 2010, 45% for 2011, and 39% for 2012), 
110 had rifampin-resistant TB by Xpert, and 15 had nega-
tive results for rifampin-resistant TB by Xpert (11 in which 
TB was not detected, 3 in which rifampin resistance was 
not detected, and 1 in which rifampin sensitivity was not 
determined). These 15 patients were subsequently found 
to have MDR TB after culture and phenotypic testing. Of 
387 patients, 295 (76%) were male, 355 (92%) were Lat-
vian, 239 (62%) lived outside Riga, 294 (76%) were HIV 
negative, and 348 (90%) had only pulmonary TB (Table 
1). Data for current homelessness was missing for 1 per-
son. Factors associated with use of Xpert appeared to be 
notification year, region, having previously had TB, site of 
disease, and HIV status (Table 1).
For the overall cohort, median time from the date sam-
ples were obtained to MDR TB treatment initiation was 27 
(95% CI 22–30, range 0–385) days. Sixteen (4%) patients 
started treatment on the day samples were obtained. When 
Xpert was not used, median delay was 40 (95% CI 33–45) 
days. When Xpert was used, median delay was 7 (95% CI 
6–8) days. Among persons for whom Xpert was used, me-
dian delay was 6 (95% CI 5–7) days when Xpert detected 
persons to have rifampin-resistant TB and 57 (95% CI 28–
99) days when Xpert showed negative results. Overall, me-
dian time to treatment initiation in Latvia decreased over 
time (Figure 3, panel A) and was relatively consistent for 
persons for whom Xpert was not used, which indicated that 
additional persons selected for Xpert testing in 2012 were 
not different in terms of their risk for a longer time to MDR 
TB treatment initiation than the initial population selected 
(Figure 3, panel B). These unadjusted figures suggest that 
time to MDR TB treatment initiation was shorter in persons 
who underwent Xpert testing (Figure 3, panel B).
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Figure 2. Conceptual framework of relationship between use of 
Xpert MTB/RIF and time to treatment initiation among patients with 
multidrug-resistant tuberculosis (MDR TB), Latvia, 2009–2012. 
Demographic and geographic variables were sex, age, country of 
birth, and region of Latvia. Clinical variables were previously having 
had tuberculosis, site of disease, and HIV status. Social risk factor 
variables were history of imprisonment, history of or current drug 
abuse, current homelessness, current dependence on alcohol. 
MTB, Mycobacterium tuberculosis; RIF, rifampin.
Decreased Time to Treatment Initiation for MDR TB
A quantile-quantile plot comparing persons for whom 
Xpert was not used with those who had rifampin-resistant 
TB by Xpert showed a linear relationship, which supported 
use of the AFT model (Figure 4, panel A). Linearity could 
only be tenuously assessed when persons who had negative 
results by Xpert were compared with either of the other 
groups. The final data quantile in both instances was highly 
influential and outlying in each plot, but could not be ig-
nored because of the small number of data points (Figure 
4, panels B, C). Given the small number of persons in this 
third group, their unexpected test results, and that they were 
likely to have had a different mechanism for a change in the 
time frame to initiating treatment, they were excluded from 
the main analysis, which resulted in 372 patients.
A Kaplan-Meier plot of time to MDR TB treatment 
initiation (Figure 5) indicated a pattern similar to that 
shown in Figure 3, panel B. This plot shows that persons 
with rifampin-resistant TB by Xpert began treatment soon-
er than those who did not have Xpert testing.
For the 372 patients, overall median time to diagnosis 
was 24 (95% CI 21–29) days (Table 2). A univariate AFT 
model showed strong evidence for an association between 
having rifampin-resistant TB by Xpert (baseline: Xpert 
not done) and reduced time to MDR TB treatment initia-
tion (time ratio 0.19, 95% CI 0.15–0.23, p<0.001; baseline 
median in model 38 days) (Table 2). This finding corre-
sponded to an absolute reduction of ≈31 days. HIV status 
also showed strong evidence for an association with time to 
treatment initiation. There was strong evidence that persons 
having extrapulmonary and pulmonary TB, having >1 so-
cial risk factor, and living in Riga led to quicker treatment 
initiation than for having only pulmonary TB, being without 
such risk factors, and living outside Riga, retrospectively.
Region, site of disease, and HIV status were associated 
with the outcome and main exposure and were included 
with a priori confounders (sex, age, and previous TB) in 
an initial multivariable model. The backwards deletion 
strategy removed HIV status. Age was included as a linear 
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Table 1. Descriptive analysis of 387 patients in MDR TB treatment cohorts, Latvia, 2009–2012* 
Variable  Total, no. (%) 
Xpert MTB/RIF, no. (%) 
Not conducted 
Conducted,  
rifampin-resistant TB 
Conducted,  
negative result 
Overall exposure 387 (100.0) 262 (67.7) 110 (28.4) 15 (3.9) 
Xpert MTB/RIF     
 Not conducted 262 (67.7) NA NA NA 
 Conducted, rifampin-resistant TB 110 (28.4) NA NA NA 
 Conducted, negative result 15 (3.9) NA NA NA 
Year reported     
 2009 114 (29.5) 114 (100.0) 0 0 
 2010 80 (20.7) 67 (83.8) 10 (12.5) 3 (3.8) 
 2011 91 (23.5) 41 (45.1) 45 (49.5) 5 (5.5) 
 2012 102 (26.4) 40 (39.2) 55 (53.9) 7 (6.9) 
Sex     
 M 295 (76.2) 200 (67.8) 88 (29.8) 7 (2.4) 
 F 92 (23.8) 62 (67.4) 22 (23.9) 8 (8.7) 
Age, y     
 <20 5 (1.3) 4 (80.0) 1 (20.0) 0 
 20–39 151 (39.0) 92 (60.9) 53 (35.1) 6 (4.0) 
 40–59 190 (49.1) 135 (71.1) 47 (24.7) 8 (4.2) 
 ≥60 41 (10.6) 31(75.6) 9 (22.0) 1 (2.4) 
Country of birth     
 Latvia 355 (91.7) 241 (67.9) 100 (28.2) 14 (3.9) 
 Other 32 (8.3) 21 (65.6) 10 (31.3) 1 (3.1) 
Region of Latvia     
 Riga 148 (38.2) 83 (56.1) 56 (37.8) 9 (6.1) 
 Other 239 (61.8) 179 (74.9) 54 (22.6) 6 (2.5) 
Social risk factors     
 None or unknown 201 (51.9) 137 (68.2) 58 (28.9) 6 (3.0) 
 >1 186 (48.1) 125 (67.2) 52 (28.0) 9 (4.8) 
Previous TB     
 No 255 (65.9) 154 (60.4) 90 (35.3) 11 (4.3) 
 Yes 132 (34.1) 108 (81.8) 20 (15.2) 4 (3.0) 
Site of disease     
 Pulmonary 348 (89.9) 245 (70.4) 91 (26.1) 12 (3.4) 
 Pulmonary and extrapulmonary 39 (10.1) 17 (43.6) 19 (48.7) 3 (7.7) 
HIV status     
 Negative 294 (76.0) 210 (71.4) 74 (25.2) 10 (3.4) 
 Positive 56 (14.5) 24 (42.9) 29 (51.8) 3 (5.4) 
 Unknown 37 (9.6) 28 (75.7) 7 (18.9) 2 (5.4) 
*Prisoners with MDR TB and persons with only extrapulmonary MDR TB were excluded. MDR TB, multidrug-resistant tuberculosis; MTB, Mycobacterium 
tuberculosis; RIF, rifampin; NA, not applicable. 
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variable (p = 0.42, by test for linearity). Region was not 
an effect modifier (p = 0.44, by test for interaction), unlike 
having previously had TB (p = 0.01, by test for interaction). 
Effect estimates for the effect of Xpert are therefore pre-
sented stratified by previous TB status (Table 3). Having 
extrapulmonary and pulmonary TB, and being a female pa-
tient were weakly associated with the outcome in the mul-
tivariable model, with a reduction in the time to treatment 
initiation (Table 2).
The effect of Xpert on time to MDR TB treatment 
initiation for persons who had not previously had TB 
differed little from the effect found by univariate analy-
sis in the fully adjusted model (time ratio 0.16, 95% CI 
0.12–0.21, Wald p<0.001; median 41 days in baseline 
strata of Xpert) (Table 3). A smaller time reduction was 
seen for persons who had previously had TB (time ra-
tio 0.34, 95% CI 0.21–0.55, Wald p<0.001; median 34 
days in baseline strata of Xpert). Thus, in this fully ad-
justed and stratified model, time to treatment initiation 
among persons found to have rifampin-resistant TB by 
Xpert was reduced by 35 days among patients who had 
previously had TB and by 22 days among those who had 
not previously had TB.
We found weak evidence for an association between 
previously having had TB and time to MDR TB treatment 
initiation in persons who had not had Xpert testing (time 
ratio 0.80, 95% CI 0.62–1.04, Wald p = 0.09). Evidence 
was stronger among persons found to have rifampin-resis-
tant TB by Xpert (effect estimate 1.69, 95% CI 1.03–2.76, 
Wald p = 0.04).
A sensitivity analysis was conducted to determine the 
effect of including year as an additional confounder in the 
model (Figure 2), although time to treatment initiation in 
the absence of Xpert testing did not appear to have changed 
during 2010–2012 (Figure 3, panel B). This inclusion re-
duced overall power because Xpert was not used in 2009 
(258 patients). Including year (as a categorical variable; p 
for linearity <0.001) had little impact on the effect estimate 
for the effect of Xpert (no previous TB 0.15, 95% CI 0.11–
0.21, Wald p<0.001; previous TB 0.45, 95% CI 0.27–0.77, 
Wald p = 0.003; baseline median 41 days) (Table 4). Effect 
estimates per year were 1.43 (95% CI 1.00–2.03) for 2011 
and 0.74 (95% CI 0.53–1.03) for 2012 (overall p<0.001; 
baseline 2010).
Inclusion of the 15 patients with MDR TB identified 
by phenotypic drug sensitivity testing, but not identified 
as having rifampin-resistant TB by Xpert, enabled Xpert 
results to be modeled as a 3-tiered variable. This inclusion 
had little influence on the effect estimate compared with 
analysis of Xpert use in 2 strata (Xpert not used vs. Xpert 
used and a positive result for rifampin-resistant TB) (Table 
4). Having a negative result by Xpert was weakly asso-
ciated with longer time to treatment initiation in persons 
who had previously had TB (effect estimate 2.97, 95% CI 
1.07–8.28, Wald p = 0.04; baseline median 41 days), but 
this association was not seen for persons who had not pre-
viously had TB. Running such a model with year included 
as a confounder (273 patients) yielded similar results, and 
the previous association appeared stronger (effect estimate 
3.63, 95% CI 1.27–10.37, Wald p = 0.02; baseline median 
41 days) (Table 4).
Discussion
An unadjusted AFT model showed strong evidence for 
an association between having rifampin-resistant TB de-
tected by Xpert and a reduction of ≈1 month in time to 
treatment initiation (time ratio 0.19, 95% CI 0.15 0.23, 
p<0.001; baseline median in model 38 days) for patients 
with MDR TB in Latvia during 2009–2012. In a fully ad-
justed model, this relationship was supported, although the 
effect of Xpert was smaller for persons who had previously 
had TB than for those with had not had TB. This finding 
corresponded to a reduction in median time to treatment 
initiation of 35 days for persons who had not previously 
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Figure 3. Relationship between use of Xpert MTB/RIF (Xpert) 
and time to treatment initiation among patients with multidrug-
resistant tuberculosis (MDR TB) Latvia, 2009–2012. Shown are 
percentages of MDR-TB patients that underwent Xpert MTB/
RIF testing (bars) and median time to treatment initiation (lines) 
with binomial distribution–derived CIs (error bars) for A) all 
patients and B) patients with and without testing by Xpert. MTB, 
Mycobacterium tuberculosis; RIF, rifampin.
Decreased Time to Treatment Initiation for MDR TB
had TB and 22 days for those who had TB. This reduction 
is paralleled by a potential lengthening of the timeframe 
in persons with negative Xpert results who had previously 
had TB, although our estimates for these persons are highly 
uncertain. Inclusion of year as a confounder had little effect 
on the results obtained, which justifies our use of data for 
2009 (when Xpert was not available in Latvia).
Data completeness in this cohort was high; thus, bias 
caused by missing data was not a major concern. Poor re-
cording of dates causing measurement error, where pres-
ent, was more likely to have been non-differential than 
differential, reducing precision around the effect estimate. 
Five patients had no recorded sampling date, but they rep-
resented a small fraction of the cohort. Patients with pul-
monary TB for whom Xpert was used were likely to have 
been those producing sputum (i.e., potentially quicker to 
give a diagnosis of drug-resistant TB even without Xpert 
testing), although absence of an increase in time to diagno-
sis among persons for whom Xpert was not used seemed 
to negate this likelihood.  We examined the impact of time 
to initiation of any MDR TB treatment regimen rather than 
a regimen tailored to second-line drug sensitivity testing. 
Given known high levels of additional drug resistance in 
MDR TB patients in Latvia, it is probable that many pa-
tients included in this study had their treatment regimen 
subsequently altered, which is not captured here and could 
be the subject of future research (14).
In South Africa, Naidoo et al. compared use of Xpert-
based and LPA-based algorithms and found a decrease of 
25 days in time to MDR TB treatment commencement 
when Xpert-based algorithms were used (12). Although the 
absolute size of such a decrease is highly context specific 
to the diagnostic pathway and available resources in each 
setting, this finding is consistent with our results.
The smaller improvement in time to treatment in per-
sons who had previously had TB and who showed rifampin 
resistance by Xpert is assumed to be because these persons 
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Figure 4. Quantile–quantile plots of time to multidrug-resistant 
tuberculosis (MDR TB) treatment initiation by use and results 
of Xpert MTB/RIF (Xpert) for patients with MDR TB, Latvia, 
2009–2012. Shown are time to MDR TB treatment initiation 
(days) for patients A) who were not tested by Xpert vs. those 
who had rifampin-resistant TB by Xpert, B) those who were not 
tested vs. those who had a negative result for rifampin-resistant 
TB, and C) those who were tested by Xpert and had positive vs. 
negative results for rifampin-resistant TB. MTB, Mycobacterium 
tuberculosis; RIF, rifampin.
Figure 5. Kaplan-Meier plot of time to treatment initiation by use 
and results of Xpert MTB/RIF in patients with multidrug-resistant 
tuberculosis (MDR TB), Latvia, 2009–2012. Shown is time to 
MDR TB treatment initiation (days) for patients who were not 
tested by Xpert MTB/RIF (dark gray line) and those who had 
rifampin-resistant TB by Xpert MTB/RIF (light gray line). MTB, 
Mycobacterium tuberculosis; RIF, rifampin.
RESEARCH
would be more likely to receive expedited MDR treat-
ment even without use of Xpert. Few patients with MDR 
TB were not given a diagnosis of rifampin-resistant TB by 
Xpert (their mechanism for a differential timeframe to start 
treatment for MDR TB is probably different than that for 
other patient categories regardless, which made interpreta-
tions across strata of Xpert more difficult). However, the 
suggested increased time to MDR TB treatment initiation 
in this group when persons had previously had TB appears 
to indicate that clinicians in Latvia trust Xpert results to 
488 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 3, March 2016
 
 
 
Table 2. Univariate and multivariable accelerated failure time models of association between Xpert MTB/RIF use and time to MDR TB 
treatment initiation for patients in MDR TB treatment cohorts, Latvia, 2009–2012* 
Variable 
Crude analysis, 
median days to 
diagnosis (95% CI) 
Univariate regression 
 
Multivariable regression 
Median days 
to diagnosis 
p value, time 
ratio (95% CI) 
Median days to 
diagnosis 
p value, time 
ratio (95% CI) 
Overall  24 (21–29) NA NA  NA NA 
Xpert MTB/RIF       
 Not conducted 40 (33–45) 38 <0.001  † † 
 Conducted, rifampin-resistant TB 6 (5–7) NA 0.19 (0.15–0.23)  † † 
Sex       
 M 26 (21–30) 30 0.08  30 0.08 
 F 21 (11–30) NA 0.80 (0.63–1.02)  NA 0.79 (0.62–1.02) 
Age, y       
 <20 64 (2‡) 29 0.98  33 0.78 
 20–39 21 (9–29) NA 1.00 (0.87–1.16)  NA 0.98 (0.84–1.14) 
 40–59 28 (22–30) NA NA  NA NA 
 >60 30 (14–48) NA NA  NA NA 
Country of birth       
 Latvia 26 (21–30) 29 0.63  NA NA 
 Other 14 (8–29) NA 0.91 (0.63–1.32)  NA NA 
Region of Latvia       
 Riga 16 (11–24) NA 0.78 (0.63–0.96)  NA 0.93 (0.75–1.16) 
 Other 30 (24–36) 32 0.02  32 0.51 
Social risk factors       
 None or unknown 30 (23–35) 32 0.03  NA NA 
 >1 22 (11–28) NA 0.79 (0.65–0.97)  NA NA 
Previous TB       
 No 24 (18–29) 28 0.39  † † 
 Yes 27 (16–35) NA 1.10 (0.89–1.36)  † † 
Site of disease       
 Pulmonary 28 (23–31) 30 0.01  30 0.05 
 Pulmonary and extrapulmonary 7 (4–11) NA 0.61 (0.43–0.86)  NA 0.69 (0.49–0.98) 
HIV status       
 Negative 29 (24–33) 31 0.003  NA NA 
 Positive 7 (4–11) NA 0.59 (0.44–0.79)  NA NA 
 Unknown 29 (14–48) NA 1.00 (0.71–1.43)  NA NA 
*Crude median time to MDR TB treatment initiation was determined (with a binomially derived CI), followed by association between use of Xpert MTB/RIF 
and time to treatment initiation in univariate and multivariable (372 patients) accelerated failure time models and median time to treatment in such models. 
Prisoners with MDR TB and persons with only extrapulmonary MDR TB were excluded; 15 patients with negative results by Xpert MTB/RIF were also 
excluded. Age was treated as a linear variable in regression analyses. The final regression model adjusted for all variables except country of birth, social 
risk factors, and HIV status. MDR TB, multidrug-resistant tuberculosis; MTB, Mycobacterium tuberculosis; RIF, rifampin; NA, not applicable. 
†Stratified results are shown in Table 3. 
‡No binomial prediction as small stratum. 
 
 
 
 
Table 3. Stratified results for multivariable accelerated failure time model of association between Xpert MTB/RIF use and time to MDR 
TB treatment initiation for patients in MDR TB treatment cohorts, Latvia, 2009–2012* 
Exposure Stratifier 
Multivariable regression, 
time ratio (95% CI) p value 
Xpert MTB/RIF Previous TB   
 Not conducted No Baseline  
 Conducted, rifampin-resistant TB No 0.16 (0.120.21) <0.001 
 Not conducted Yes Baseline  
 Conducted, rifampin-resistant TB Yes 0.34 (0.21–0.55) <0.001 
Previous TB Xpert MTB/RIF   
 No Not conducted Baseline  
 Yes Not conducted 0.80 (0.62–1.04) 0.09 
 No Conducted, rifampin-resistant TB Baseline  
 Yes Conducted, rifampin-resistant TB 1.69 (1.03–2.76) 0.04 
*Association between use of Xpert MTB/RIF and time to MDR TB treatment initiation was stratified by the effect modifier previous tuberculosis. 
Association between previous tuberculosis and time to MDR TB treatment initiation was stratified by Xpert use. There were 372 patients in the model. All 
results derived from the final model shown in Table 2. Median in baseline strata of Xpert MTB/RIF and previous tuberculosis was 41 days. MTB, 
Mycobacterium tuberculosis; RIF, rifampin. MDR TB, multidrug-resistant tuberculosis; NA, not applicable. 
 
Decreased Time to Treatment Initiation for MDR TB
the extent that clinical suspicion of MDR TB, which might 
expedite starting treatment for MDR TB in the absence of 
Xpert results, is overridden. Such delays could have nega-
tive consequences for patients in terms of having a success-
ful treatment outcome and highlights the need for accurate 
clinical judgement in diagnostic algorithms.
Latvia also has a few TB cases each year that have 
discordant results in the opposite direction. A total of 7 
patients in 2013 had rifampin-resistant TB by Xpert, but 
5 (3 of which showed rifampin resistance by LPA) had 
rifampin-sensitive results by BACTEC (Becton, Dickinson 
and Company, Franklin Lakes, NJ, USA), and 2 were not 
culture positive by BACTEC or on solid media.
Sensitivity of Xpert for detection of rifampin resis-
tance has been documented in many settings, and specific 
mutations and mixed infections are believed to play a role 
(5,20,21). No interaction was seen in analysis by residential 
region, which is noteworthy given the time lag incurred by 
transporting samples to Riga for patients living elsewhere 
in Latvia, but a positive sign for the over-arching function-
ality of the TB program.
We made adjustments for temporal changes in our sen-
sitivity analyses. It was reassuring to see a relatively steady 
time to treatment initiation among patients for whom Xpert 
was not used, particularly given the change in target popu-
lations. This study was restricted to MDR TB treatment 
cohorts, whereby inclusion in a particular year cohort is 
determined by the date on which treatment started. Use of 
Xpert could have also reduced the proportion of patients 
who did not start treatment because earlier use of treatment 
might have reduced the likelihood of death and pretreat-
ment default.
Our study in Latvia suggests that implementing Xpert 
as an early-stage diagnostic tool from which treatment 
decisions are rapidly made reduces the time to MDR TB 
treatment initiation. This implementation not only probably 
benefits patients with MDR TB but might also reduce noso-
comial and community transmission (1). Other countries 
should undertake similar research to evaluate the effect 
of Xpert on time to treatment initiation and treatment out-
comes. Careful monitoring of time to treatment initiation 
could provide valuable performance data for national TB 
programs, around which targets could be set.
Although cost implications of introducing Xpert are 
variable in different settings, cost and affordability analy-
ses suggest its viability as a diagnostic tool for detecting 
MDR TB, particularly in settings that have a high burden of 
MDR TB in which rifampin resistance has a good PPV for 
detecting MDR TB (16,22). Nevertheless, implementation 
of Xpert needs to be considered carefully in terms of how 
it is introduced into diagnostic algorithms, where machines 
are located, how clinicians interpret test results, and the 
common sites of TB in a particular population.
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